<DOC>
	<DOC>NCT00794365</DOC>
	<brief_summary>The primary objective of this Post-Marketing Study is to monitor the safety of a novel smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical practice for 12 weeks among Filipino smokers. The secondary objective is to further evaluate the effectiveness of Varenicline (Champix™) as an aid in smoking cessation based on the 7-day point prevalence of smoking cessation</brief_summary>
	<brief_title>Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients</brief_title>
	<detailed_description>The study will enroll smoking patients.</detailed_description>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Smoking adults aged ≥ 18 years intending to quit tobacco use who are prescribed Varenicline (Champix™) by their Physicians and those who are prescribed with Varenicline (Champix™) for the first time. Subjects in whom varenicline (Champix™) may be taken in a manner that is not according to the approved local product document. Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception Subjects with known hypersensitivity to varenicline.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Smoking; smoking cessation; Philippines; Varenicline</keyword>
</DOC>